Ankur Bahl

Publications

• Research Article   
  Quality of life in cancer patients receiving chemotherapy vs immunotherapy in tertiary hospital settings
  Author(s): Marwan Mahtook*, Abul Kalam Najmi, Abhishek Raj and Ankur Bahl
  
  There are various therapies in the management of tumours. Immunotherapy is one of the most promising developed treatments included in the second line of many treatment protocols. The quality of life concept was recently evaluated in numerous RCTs to support the evidence in the selection of those therapies in treatment regimens. Aim: To evaluate the quality of life in cancer patients and compare it in two intervention groups, first received chemotherapy alone or plus immunotherapy and second only immunotherapy. Study design and method: Observational cross-sectional study, the study population of 92 cancer patients divided into two groups (Group A; chemo alone or with immunotherapy, and Group B Immunotherapy alone) visited Fortis Memorial Research Institute's chemo-daycare the period between September 11th, 2020 and April 28th, 2021. They evaluated QOL by adminis.. Read More»
  

  Abstract HTML PDF